The Mid Atlantic Fund (New York)
As Director with the Mid Atlantic Fund, Carl Jaramillo sources new investment opportunities, screens potential investments, and conducts due diligence on these opportunities. In addition, after an investment has been made, he actively supports Mid Atlantic portfolio companies in a variety of ways, including corporate business development activities and Prior to his role with Mid Atlantic, Carl was a consultant with Cambridge Pharma Consultancyfinancial modeling and forecasting, and assists with future rounds of financing. (since acquired by IMS Consulting) where he provided research and analysis to top ten pharmaceutical companies on strategic issues. While at Cambridge, Carl was based in both New York and Shanghai, China, working extensively in both the US market and the Chinese market. He speaks Mandarin Chinese. Before joining Cambridge, Carl performed market analysis for Quintiles Transnational. There he conducted research on potential blockbuster Phase III/registered drugs as targets for new business opportunities and studied the commercial viability of new products for the Quintiles corporate venture capital unit (Pharma Bio).
Carl is a graduate of Cornell University, with degrees in Management, with a concentration in health care, and Biology, with a concentration in molecular biology, health, and medicine. He completed his undergraduate course of study in two years. While at Cornell, Carl worked for two years in a molecular biology laboratory, performing PCR, vector legation, DNA extraction, and purification to study the enzymes regulating cell membranes.